Delonix Bioworks Announces First Participant Dosed in Phase 1 Clinical Trial of Next-Generation MenB OMV Vaccine DX-104 in China

Phase 1DX-104Positive

AI Analysis

Summary

Delonix Bioworks announced the first participant dosed in a Phase 1 clinical trial of DX-104, a next-generation MenB OMV vaccine, in China. The trial represents the initial clinical evaluation of the company's genetically engineered bacterial vaccine candidate.

Clinical Trial Data

Phase

Phase 1

Outcome Details

First participant dosed in Phase 1 clinical trial

Importance:5/10

Sentiment:

0.60

Phase 1 trialvaccineMenBChinabacterial vaccineclinical trial initiation

Related Companies

$GBIO $CHHE $TRAX

Read the original article

Published by PR Newswire Biotech on July 13, 2026 12:00 PM

Read Original